Search results for "NATRIURETIC PEPTIDE"

showing 10 items of 178 documents

Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation

2017

Elevated carbohydrate antigen 125 (CA125) and N-terminal pro-brain natriuretic peptide (NTproBNP) have been associated with adverse outcome after transcatheter aortic valve implantation (TAVI). This study performs a comparison of both biomarkers for prognosis after TAVI. The study includes 363 patients. The primary end point was all-cause death or readmission for worsening congestive heart failure within 1 year after TAVI, and this end point occurred in 16% of the population. The optimal cutoff to predict the primary end point was 18.4 U/ml for CA125 and 2,570 ng/L for NTproBNP. Elevated CA125 levels were present in 52% and were associated with a higher rate of the primary end point (27% vs…

Malemedicine.medical_specialtyTranscatheter aorticmedicine.drug_classPopulation030204 cardiovascular system & hematologyRisk AssessmentTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicinePredictive Value of TestsGermanyInternal medicineNatriuretic Peptide BrainNatriuretic peptideClinical endpointHumansMedicine030212 general & internal medicineeducationAged 80 and overHeart Failureeducation.field_of_studybusiness.industryAortic Valve StenosisPrognosismedicine.diseasePeptide FragmentsCA-125 AntigenPredictive value of testsHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCarbohydrate antigenBiomarkersN-terminal pro-Brain Natriuretic PeptideThe American Journal of Cardiology
researchProduct

Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with …

2010

Aim Elevated brain natriuretic peptide (BNP) and tumour marker antigen carbohydrate 125 (CA125) levels have shown to be associated with higher risk for adverse outcomes in patients with acute heart failure (AHF). Nevertheless, no attempt has been made to explore the utility of combining these two biomarkers. We sought to assess whether CA125 adds prognostic value to BNP in predicting 6-month all-cause mortality in patients with AHF. Methods and results We analysed 1111 consecutive patients admitted for AHF. Antigen carbohydrate 125 (U/mL) and BNP (pg/mL) were measured at a median of 72 ± 12 h after instauration of treatment. Antigen carbohydrate 125 and BNP were dichotomized based on propos…

Malemedicine.medical_specialtyendocrine system diseasesHeart diseasemedicine.drug_classKaplan-Meier EstimateGastroenterologyRisk AssessmentAntigenInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumansTumor markerAgedAged 80 and overHeart Failurebusiness.industryProportional hazards modelMiddle Agedmedicine.diseaseBrain natriuretic peptidePrognosisEndocrinologyHeart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicineRisk assessmentbusinesshormones hormone substitutes and hormone antagonistsBiomarkersEuropean heart journal
researchProduct

Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

2020

Abstract Background Carbohydrate antigen 125 (CA125) and B-type natriuretic peptides are surrogate markers of congestion in patients with acute heart failure (AHF). The aim of the study was to assess the association between CA125 and NT-proBNP and congestion parameters in patients with AHF. Methods and results Prospective multicentre observational study that included 191 patients hospitalised for AHF. We recorded the presence of pleural effusion, peripheral oedema and inferior vena cava (IVC) diameter during the first 24–48 h after admission and evaluated their independent association with CA125 concentrations and the amino-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP). Th…

Malemedicine.medical_specialtyendocrine system diseasesmedicine.drug_classPleural effusionPeripheral edemaInferior vena cavaVentricular Function LeftInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIn patientProspective StudiesAgedAged 80 and overHeart FailureEjection fractionbusiness.industryStroke VolumeMiddle AgedPrognosismedicine.diseasePeptide Fragmentsmedicine.veinHeart failureCardiologySerum ca125Femalemedicine.symptombusinessBiomarkersMedicina Clínica (English Edition)
researchProduct

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

2007

The aim of the present study was to evaluate the effects of a normal-sodium (120 mmol sodium) diet compared with a low-sodium diet (80 mmol sodium) on readmissions for CHF (congestive heart failure) during 180 days of follow-up in compensated patients with CHF. A total of 232 compensated CHF patients (88 female and 144 male; New York Heart Association class II–IV; 55–83 years of age, ejection fraction <35% and serum creatinine <2 mg/dl) were randomized into two groups: group 1 contained 118 patients (45 females and 73 males) receiving a normal-sodium diet plus oral furosemide [250–500 mg, b.i.d. (twice a day)]; and group 2 contained 114 patients (43 females and 71 males) recei…

Malemedicine.medical_specialtyfood.dietLow sodium dietPlasma renin activityGastroenterologyPatient Readmissionchemistry.chemical_compoundfoodFurosemideInternal medicineNatriuretic Peptide BrainReninmedicineHumansDiureticsAldosteroneAgedAged 80 and overHeart FailureEjection fractionAldosteronebusiness.industryFurosemideSodium DietaryGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseBrain natriuretic peptideCombined Modality TherapySurvival AnalysisEndocrinologyTreatment OutcomechemistryHeart failureFemalebusinessmedicine.drugLow sodiumFollow-Up StudiesClinical science (London, England : 1979)
researchProduct

Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study

2015

Background and Aims Compensatory renal hypertrophy following unilateral nephrectomy (UNX) occurs in the remaining kidney. However, the long-Term cardiac adaptive process to UNX remains poorly defined in humans. Our goal was to characterize myocardial structure and function in living kidney donors (LKDs), approximately 12 years after UNX. Methods and Results Cardiac function and structure in 15 Italian LKDs, at least 5 years after UNX (median time from donation = 8.4 years) was investigated and compared to those of age and sex matched U.S. citizens healthy controls (n = 15). Standard and speckle tracking echocardiography (STE) was performed in both LKDs and controls. Plasma angiotensin II, a…

Malemedicine.medical_specialtylcsh:MedicinePilot Projectschemistry.chemical_compoundInternal medicineNatriuretic Peptide BrainLiving DonorsmedicineHumanslcsh:ScienceAldosteroneKidney transplantationAgedKidneyMultidisciplinaryAldosteronebusiness.industryAngiotensin IIMyocardiumlcsh:RMyocardial adaptations Kidney donorsCompensatory renal hypertrophyHeartMiddle AgedUnilateral nephrectomymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareKidney TransplantationAngiotensin IIPeptide FragmentsStructure and functionCardiovascular physiologyCross-Sectional Studiesmedicine.anatomical_structureEndocrinologychemistryCardiologylcsh:QFemalebusinessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieAtrial Natriuretic FactorProcollagenResearch ArticlePLOS ONE
researchProduct

Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure.

2010

Abstract Background The prognostic utility of combining serial measurements of brain natriuretic peptide (BNP) and antigen carbohydrate 125 (CA125) is largely unknown. The aim of this work is to assess the prognostic utility of serial measurements of BNP, CA125, and their optimal combination for predicting long-term mortality, following a hospitalization for acute heart failure (AHF). Methods and results We analyzed 293 consecutive patients admitted with AHF where CA125 and BNP were measured at discharge (T1) and at the first ambulatory visit (T2: median 31days after discharge). Biomarkers were evaluated as snapshot determinations or as serial changes in absolute, relative or categorical ch…

Malemedicine.medical_specialtymedicine.drug_classCohort StudiesText miningAntigenRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIntensive care medicineAgedAged 80 and overHeart FailureProportional hazards modelbusiness.industryMiddle AgedBrain natriuretic peptidemedicine.diseaseHeart failureCA-125 AntigenAcute DiseaseCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyFollow-Up StudiesInternational journal of cardiology
researchProduct

Analysis of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes

2009

Background The N-terminal portion of brain natriuretic peptide (NT-proBNP) has been identified as an indicator of prognosis in different cardiovascular diseases. The objective of this study was to determine the utility of measuring plasma NT-proBNP levels in patients with acute coronary syndromes. Methods and results We studied 66 patients admitted in our division for acute coronary syndromes. Patients underwent a venous blood sample within 24 h from the admission to determine NT-proBNP levels. Increasing plasma levels of NT-proBNP (in tertiles) was associated with a greater history of hypertension and current smoking, whereas biochemical parameters were associated with higher level of crea…

Malemedicine.medical_specialtymedicine.drug_classCreatineRisk AssessmentVentricular Dysfunction Leftchemistry.chemical_compoundPredictive Value of TestsRecurrenceNt-proBNP N-terminal pro-B-type natriuretic peptide acute coronary sydromeInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideCreatine Kinase MB FormHumansIn patientHospital MortalityAcute Coronary SyndromeAgedInpatientsCreatininebiologybusiness.industryTroponin IGeneral MedicineLength of StayMiddle AgedPrognosisBrain natriuretic peptidePeptide FragmentschemistryCreatininePredictive value of testsCardiologybiology.proteinFemaleCreatine kinaseN terminal pro b type natriuretic peptideCardiology and Cardiovascular MedicinebusinessBiomarkersCoronary Artery Disease
researchProduct

Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the Ath…

2005

Aims Metalloproteinases are proteolytic enzymes, which decompose the extracellular matrix, influence cardiac remodelling, and are inhibited by tissue inhibitor of metalloproteinases (TIMPs). Little is known about the prognostic impact of the TIMP-1/matrix metalloproteinase complex in patients with future cardiovascular death. Methods and results In 1979 patients with suspected coronary artery disease (CAD), TIMP-1 has been determined at baseline. Among 1945 (98.4%) patients with a mean follow-up period of 2.6±1.2 years, 75 patients died because of cardiovascular causes. Mean concentrations of TIMP-1 were higher among patients who experienced a fatal cardiovascular event than among those who…

Malemedicine.medical_specialtymedicine.drug_classDiseaseCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicinemedicineNatriuretic peptideHumansTissue Inhibitor of Metalloproteinase-1business.industryHazard ratioConfoundingProteolytic enzymesTissue inhibitor of metalloproteinaseMiddle Agedmedicine.diseasePrognosisEndocrinologyCardiovascular DiseasesCirculatory systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesEuropean heart journal
researchProduct

Multiple biomarkers and atrial fibrillation in the general population.

2014

BACKGROUND: Different biological pathways have been related to atrial fibrillation (AF). Novel biomarkers capturing inflammation, oxidative stress, and neurohumoral activation have not been investigated comprehensively in AF. METHODS AND RESULTS: In the population-based Gutenberg Health Study (n = 5000), mean age 56 ± 11 years, 51% males, we measured ten biomarkers representing inflammation (C-reactive protein, fibrinogen), cardiac and vascular function (midregional pro adrenomedullin [MR-proADM], midregional pro atrial natriuretic peptide [MR-proANP], N-terminal pro-B-type natriuretic peptide [Nt-proBNP], sensitive troponin I ultra [TnI ultra], copeptin, and C-terminal pro endothelin-1), a…

Malemedicine.medical_specialtymedicine.drug_classEpidemiologyPopulationCardiologylcsh:MedicineCopeptinRisk FactorsInternal medicineTroponin IAtrial FibrillationmedicineNatriuretic peptideMedicine and Health SciencesHumansPublic and Occupational Healtheducationlcsh:ScienceAgededucation.field_of_studyMultidisciplinaryModels Statisticalbiologybusiness.industrylcsh:RAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseTroponinCardiovascular DiseasesPopulation SurveillanceCardiologybiology.proteinBiomarker (medicine)Femalelcsh:QbusinessArrhythmiaBiomarkersResearch ArticlePLoS ONE
researchProduct

Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.

2018

Abstract Background Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. Methods 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12.5%), and 135 with HFpEF (12.5%). We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), soluble suppression of tumorigenicity (ST2), galectin-…

Malemedicine.medical_specialtymedicine.drug_classGalectin 3030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin TInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overHeart FailureEjection fractionbiologyTroponin Tbusiness.industryHazard ratioStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisPeptide FragmentsDeathHeart failureChronic Diseasebiology.proteinCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational journal of cardiology
researchProduct